Global Recombinant DNA Drug Market Growth (Status and Outlook) 2025-2031

According to this study, the global Recombinant DNA Drug market size will reach US$ 311339 million by 2031.

Recombinant DNA drugs are therapeutic agents produced using recombinant DNA technology, which involves inserting a gene encoding a therapeutic protein into a host cell (such as bacteria, yeast, or mammalian cells) to enable large-scale production of that protein. These drugs are typically biologics that mimic or supplement the function of naturally occurring substances in the body.

United States market for Recombinant DNA Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Recombinant DNA Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Recombinant DNA Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Recombinant DNA Drug players cover Novo Nordisk, Amgen, Eli Lilly, Sanofi, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Recombinant DNA Drug Industry Forecast” looks at past sales and reviews total world Recombinant DNA Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant DNA Drug sales for 2025 through 2031. With Recombinant DNA Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant DNA Drug industry.

This Insight Report provides a comprehensive analysis of the global Recombinant DNA Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Recombinant DNA Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant DNA Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant DNA Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant DNA Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant DNA Drug market by product type, application, key players and key regions and countries.

Segmentation by Type:
Fusion Protein
Recombinant Growth Factor
Recombinant Hormone
Recombinant Interferon
Recombinant Interleukin
Recombinant Coagulation Factor
Other

Segmentation by Application:
Cancers
Autoimmune Diseases
Metabolic Disorders
Infectious Diseases

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Amgen
Eli Lilly
Sanofi
Bayer
Bristol-Myers Squibb
GlaxoSmithKline
AbbVie
Sandoz
Biogen
Pfizer
GenSci
3SBIO
Organon Pharma
Roche
Swedish Orphan Biovitrum
CSPC
Johnson & Johnson
Merck
Takeda

Please note: The report will take approximately 2 business days to prepare and deliver. Show more